Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
---|
04/30/2002 | US6380219 For therapy of arthritis, cancer, tissue ulceration, restenosis, peridontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, sepsis, septic shock |
04/30/2002 | US6380218 For therapy of respiratory, allergic, and inflammatory disorders comprising asthma, chronic obstructive pulmonary disease, acute respiratory disease syndrome, pulmonary hypersensitivity, and allergic rhinitis in a mammal |
04/30/2002 | US6380211 For treating diabetes |
04/30/2002 | US6380184 For increased production of wool, milk, and meat by treating animals with therapeutically effective amount of compound |
04/30/2002 | US6379953 An activated leukocyte cell adhesion molecule bearing mesenchymal stem cell; for accelerating differentiation of bone morphogenic proteins; bone repair therapy |
04/30/2002 | US6379648 Biodegradable glass compositions and methods for radiation therapy |
04/30/2002 | CA2300666C Method for treating dystonia with botulinum toxin type b |
04/30/2002 | CA2221417C Anhydrous alendronate monosodium salt formulations |
04/30/2002 | CA2172114C New thiophene compounds, process for preparing the same and pharmaceutical compositions containing them |
04/26/2002 | CA2324631A1 A substance or composition for the treatment of cancer |
04/25/2002 | WO2002033100A2 Regulation of human adenylate cyclase, type iv |
04/25/2002 | WO2002033099A2 Human kinases |
04/25/2002 | WO2002033085A2 Wisp polypeptides and therapeutical applications thereof |
04/25/2002 | WO2002033079A2 Human g-protein coupled receptor and uses thereof |
04/25/2002 | WO2002032953A2 Pregnancy-associated plasma protein-a2 (papp-a2) |
04/25/2002 | WO2002032901A2 Bridged piperazine derivatives |
04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
04/25/2002 | WO2002032894A1 Substituted imidazoles useful in the treatment of inflammatory diseases |
04/25/2002 | WO2002032879A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
04/25/2002 | WO2002032872A1 Nitrogenous aromatic ring compounds |
04/25/2002 | WO2002032861A2 Orally active salts with tyrosine kinase activity |
04/25/2002 | WO2002032456A1 Remedies or preventives for rheumatoid arthritis |
04/25/2002 | WO2002032441A1 Bone metabolism improving agent |
04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
04/25/2002 | WO2002032411A2 Combination of statins and sorbitol dehydrogenase inhibitors |
04/25/2002 | WO2002032407A2 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
04/25/2002 | WO2002032406A2 Methods and products related to pulmonary delivery of polysaccharides |
04/25/2002 | WO2002032397A2 Electroprocessing in drug delivery and cell encapsulation |
04/25/2002 | WO2002032377A2 Estrogen receptor modulators |
04/25/2002 | WO2002032373A2 Estrogen receptor modulators |
04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
04/25/2002 | WO2002010137A3 Indazole derivatives as JNK inhibitors |
04/25/2002 | WO2001093847A3 Compositions, kits, and methods for promoting defined health benefits |
04/25/2002 | WO2001093833A3 Kits and methods for optimizing the efficacy of chondroprotective compositions |
04/25/2002 | WO2001093831A3 Low carbohydrate compositions, kits thereof, and methods of use |
04/25/2002 | WO2001092340A3 Use of interleukin-4 antagonists and compositions thereof |
04/25/2002 | WO2001081333A3 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
04/25/2002 | WO2001072831A3 Immunoregulator |
04/25/2002 | WO2001070208A3 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate |
04/25/2002 | WO2001068880A3 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
04/25/2002 | WO2001058891A3 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage |
04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
04/25/2002 | WO2001042471A3 Polypeptides and polynucleotides encoding same |
04/25/2002 | WO2001002369A3 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
04/25/2002 | US20020049344 New vitamin d derivatives with carbo-or heterocyclic substituents at c-25, a process for their production, intermediate products and their use for producing medicaments |
04/25/2002 | US20020049281 Contacting with crosslinking agents so as to form two or more chemically distinct crosslinks between hyaluronic acid and the polymer; products with medical applications |
04/25/2002 | US20020049254 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
04/25/2002 | US20020049238 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
04/25/2002 | US20020049236 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
04/25/2002 | US20020049233 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
04/25/2002 | US20020049231 S(-)-3-aminothalidomide; treating wide variety of diseases including diabetic retinopathy |
04/25/2002 | US20020049226 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis |
04/25/2002 | US20020049224 Alpha v integrin receptor antagonists |
04/25/2002 | US20020049222 Cyclopentyl modulators of chemokine receptor activity |
04/25/2002 | US20020049220 Substituted azoles |
04/25/2002 | US20020049215 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
04/25/2002 | US20020049202 Administering halogenated amidino or oxyamidino compound to treat diseases caused by nitric oxide synthase |
04/25/2002 | US20020049198 Administering to a patient having or at risk of having osteoarthritis, a therapeutically effective amount of an bicyclicaromatic or heteroaromatic compound containing amine and hydroxy groups |
04/25/2002 | US20020049196 Hexahydro-pyrazolo-(4,3-c)pyridine derivatives useful for increasing the endogenous production or release of growth hormone in a human or other animal, thus treat or prevent osteoporosis |
04/25/2002 | US20020049185 Malonic acid based matrix metalloproteinase inhibitors |
04/25/2002 | US20020049151 Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors |
04/25/2002 | US20020048794 Polypeptides for use in the diagnosis and treatment of skin disorders, cancer, vision and demyelination defects, inflammation, glomerculonephritis, Kaposi's sarcoma, angiogenesis, sarcoidosis, osteoarthritis and aneurysm |
04/25/2002 | US20020048786 Nucleotide sequences for use in the treatment of infections, arthritis, karposi's sarcoma, allergies, asthma, nervous system and autoimmune diseases |
04/25/2002 | US20020048785 Novel polypeptides within the tumor necrosis factor receptor superfamily and uses therefor |
04/25/2002 | US20020048564 Oligodeoxyribonucleotide having one or more NF- kappa B binding sites. |
04/25/2002 | DE10051321A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are potent neurokinin antagonists, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
04/25/2002 | DE10051320A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are neurokinin antagonists having a long duration of action, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
04/25/2002 | CA2818654A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
04/25/2002 | CA2464121A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
04/25/2002 | CA2464092A1 Electroprocessing in drug delivery and cell encapsulation |
04/25/2002 | CA2426592A1 Combination of statins and sorbitol dehydrogenase inhibitors |
04/25/2002 | CA2426487A1 Ep4 receptor inhibitors to treat rheumatoid arthritis |
04/25/2002 | CA2426337A1 Substituted imidazoles useful in the treatment of inflammatory diseases |
04/25/2002 | CA2426271A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
04/25/2002 | CA2426083A1 Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis |
04/25/2002 | CA2425963A1 Human kinases |
04/25/2002 | CA2424729A1 Estrogen receptor modulators |
04/25/2002 | CA2424726A1 Estrogen receptor modulators |
04/25/2002 | CA2424689A1 Orally active salts with tyrosine kinase activity |
04/25/2002 | CA2423789A1 Bridged piperazine derivatives |
04/25/2002 | CA2423469A1 Methods and products related to pulmonary delivery of polysaccharides |
04/25/2002 | CA2405906A1 Remedies or preventives for rheumatoid arthritis |
04/24/2002 | EP1199372A2 Polymorphisms in the human P2X7 gene |
04/24/2002 | EP1199074A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
04/24/2002 | EP1199072A2 Method of treating cartilage damage |
04/24/2002 | EP1199067A2 Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists |
04/24/2002 | EP1198570A1 Monomeric protein of the tgf-beta family |
04/24/2002 | EP1198568A1 Compositions and methods for the treatment of immune related diseases |
04/24/2002 | EP1198479A1 Neovascular-targeted immunoconjugates |
04/24/2002 | EP1198467A1 5-nitrofurfural derivatives |
04/24/2002 | EP1198246A2 Methods for preventing or attenuating pathoangiogenic conditions by using the gbs-toxin (cm101) receptor as a vaccine |
04/24/2002 | EP1198241A1 Novel proteins |
04/24/2002 | EP1198235A1 Method of promoting bone growth with hyaluronic acid and growth factors |
04/24/2002 | EP1198231A1 Bicyclic antagonists selective for the(alpha)v(beta)3 integrin |
04/24/2002 | EP1007063A4 Bone regeneration in osteoporosis using human bone marrow mesenchymal cells |
04/24/2002 | CN1346364A 16-hydroxyestratrienes as selective estrogens |
04/24/2002 | CN1346344A Substituted 2-aminobenzamide caspase ihibitors and the use thereof |
04/24/2002 | CN1346272A Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
04/24/2002 | CN1346271A Quinazoline derivatives as angiogenesis inhibitors |
04/24/2002 | CN1346269A Calcilytic compounds |